Navigation Links
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
Date:5/9/2013

R-181: Implications for Labeling", Webster, L., et al. 
  • Date: June 20, 2013, 7:30 a.m. – 9:30 a.m. Pacific Time
  • Poster 1598130: "Opioids With Lower Brain Uptake Are Less Recognizable in Rat Drug Discrimination Tests and thus Potentially Less Subject to Abuse", Harrison, S., et al. 
  • Date: June 19, 2013, 12:00 p.m. – 2:00 p.m. Pacific Time
  • Conference Call to Discuss First Quarter 2013 Financial ResultsNektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time today, Thursday, May 9, 2013.

    This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, June 10, 2013. To access the conference call, follow these instructions:Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)Passcode: 36590300 (Nektar Therapeutics is the host)In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

    About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily
    '/>"/>

    SOURCE Nektar Therapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
    2. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
    3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
    5. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
    6. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
    7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
    8. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
    9. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
    10. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
    11. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... BOSTON , January 23, 2015 ... development company, is delighted to announce that the Malcolm ... Miles Congreve (Vice President of Chemistry), Fiona ... Weir (Chief Executive Officer and co-founder) for the seminal ...
    (Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
    (Date:1/22/2015)... Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today reported ... 31, 2014.  Global revenue for the Company,s ... million, a new quarterly revenue record, as compared to ...
    Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
    ... ... ... , , , ... ...
    ... ... ... ... ...
    Cached Medicine Technology:INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 2INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 3INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 4Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 2Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 3Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 4Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 5Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 6Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 7Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 8Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 9Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 10Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 11Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 12Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update 13
    (Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to announce ... Services at North Carolina State’s College of Veterinary Medicine ... Award for Distinguished Volunteer Service—the organization’s highest award. ... of volunteer experts to direct its work to improve ...
    (Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
    (Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
    (Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
    Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
    ... be the best drug to control high blood ... according to a new study. ,At The ... was shown to be statistically significantly better than ... among African-American hypertensive patients in a multicenter, randomized, ...
    ... mutations accelerate the series of cell// deaths that lead ... University of Wisconsin-Madison, growing old happens when the genetic ... deaths that may lead to hearing loss, loss of ... structures and less number of red bloods cells. The ...
    ... Srivastava and his colleagues of UT Southwestern Medical Center of ... responsible for aortic valve disease. Aortic valve disease is a ... ,The study was done in five generations of a ... the 11 members of the family who were affected by ...
    ... India has now issued a list of permitted additives ... grades that should be followed in the manufacture of ... after a number of reports claimed that individuals found ... adverse effects. ,The substances permitted according to ...
    ... and spread in humans// by inhaling spores from infected animals. It ... a report of Anthrax among the farm animals of the state ... the health officials. ,Kerala has also imposed ban on farm ... market town on the border of Kerala and Tamil Nadu that ...
    ... of instituting a pharmaceutical price// index similar to the ... fluctuations for price-related decisions. At present, the government is ... ORG-IMS for drug price revisions. However it is felt ... the retail audit of formulations is not quite effective. ...
    Cached Medicine News:Health News:Hypertension Drug of Choice for African Americans 2Health News:Mutations in NOTCH1 cause an early developmental defect in the aortic valve 2Health News:Anthrax Scare In Tamil Nadu State of India 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: